174 related articles for article (PubMed ID: 18628457)
1. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
[TBL] [Abstract][Full Text] [Related]
2. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
Kiyoi H; Ohno R; Ueda R; Saito H; Naoe T
Oncogene; 2002 Apr; 21(16):2555-63. PubMed ID: 11971190
[TBL] [Abstract][Full Text] [Related]
4. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
5. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
Masson K; Liu T; Khan R; Sun J; Rönnstrand L
Br J Haematol; 2009 Jul; 146(2):193-202. PubMed ID: 19438505
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
Razumovskaya E; Masson K; Khan R; Bengtsson S; Rönnstrand L
Exp Hematol; 2009 Aug; 37(8):979-89. PubMed ID: 19477218
[TBL] [Abstract][Full Text] [Related]
7. Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant.
Ishiko J; Mizuki M; Matsumura I; Shibayama H; Sugahara H; Scholz G; Serve H; Kanakura Y
Oncogene; 2005 Dec; 24(55):8144-53. PubMed ID: 16091740
[TBL] [Abstract][Full Text] [Related]
8. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
[TBL] [Abstract][Full Text] [Related]
9. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
[TBL] [Abstract][Full Text] [Related]
10. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
[TBL] [Abstract][Full Text] [Related]
11. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
[TBL] [Abstract][Full Text] [Related]
12. The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation.
Vu HA; Xinh PT; Kano Y; Tokunaga K; Sato Y
Biochem Biophys Res Commun; 2009 Jun; 383(3):308-13. PubMed ID: 19345670
[TBL] [Abstract][Full Text] [Related]
13. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
14. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
15. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
[TBL] [Abstract][Full Text] [Related]
16. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.
Choudhary C; Olsen JV; Brandts C; Cox J; Reddy PN; Böhmer FD; Gerke V; Schmidt-Arras DE; Berdel WE; Müller-Tidow C; Mann M; Serve H
Mol Cell; 2009 Oct; 36(2):326-39. PubMed ID: 19854140
[TBL] [Abstract][Full Text] [Related]
17. Activation of the EGF receptor by insertional mutations in its juxtamembrane regions.
Sorokin A
Oncogene; 1995 Oct; 11(8):1531-40. PubMed ID: 7478577
[TBL] [Abstract][Full Text] [Related]
18. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
